What’s with All the Bio M&A in 2019?: A Quick Take

2019 M&A Activity Overview

• By March 2019, biopharma M&A activity reached $94 billion, compared to $123 billion for the entire year of 2018.
• Major early 2019 transactions include Bristol-Myers Squibb acquiring Celgene, Takeda acquiring Shire, and the GE Biopharma divestiture.

Drivers of the 2019 "Perfect Storm"

• Patent Cliffs: Major companies lost exclusivity on key drugs in 2018 (Roche lost Zolair/Rituxan; Pfizer lost Lyrica; GSK lost Advair), creating an urgent need to replace revenue streams.
• Capital Availability: The top 10 biopharma companies entered 2018 with approximately $150 billion in cash on their balance sheets.
• Valuation Compression: The NASDAQ biotechnology index fell 7% between January and December 2018, making targets more attractive and vulnerable to acquisition.
• Buyer Psychology: While general market sectors saw trading downturns, pharma stocks strengthened at the end of 2018, encouraging buyers to re-examine previously overlooked targets.

Strategic Shifts: Platform Acquisitions and Moats

• Gene Therapy as a Moat: Acquisitions like Roche's Spark and Novartis's Avexis are driven by the desire to secure AAV9 vector platforms for sustained future cash flows, rather than just single assets.
• Manufacturing as a Platform: Buyers prioritize companies with specialized end-to-end manufacturing capabilities (e.g., Spark in Philadelphia, Unicure, Denisis) which serve as critical infrastructure for gene therapy modalities.
• Supply Chain Security: Novartis's acquisitions of AAA and Endocyte secured supply chains for specific radioisotopes, creating an enablement platform for radio-labeled oncology.
• Definition of a Bio Platform: Platforms are defined not only by proprietary drug discovery methodology but by shared R&D, know-how, and the ability to scale multiple assets or modalities.

Capital Deployment Strategies: Rent vs. Buy

• Risk Aversion in Early Stages: Most corporate buyers prefer "renting" via licensing or corporate venture arm investments to assess R&D productivity before committing to acquisitions.
• Option Agreements: Common structures allow pharma to outsource R&D without immediate P&L impact, reserving the right to acquire later based on data milestones.
• Late-Stage Preference: Typical acquisitions target late-stage or marketed assets to ensure proof of concept (Phase II data) before "doubling down."
• Oncology Exception: In highly competitive areas like immuno-oncology, buyers are making large bets at Phase I or pre-human data stages due to the intensity of the race.

Advice for Startup Executives

• Early Engagement: Founders should identify high-priority therapeutic areas for major pharma and engage potential partners early to ensure alignment of vision.
• Internal Champions: Successful deals often hinge on securing a committed internal champion (e.g., Head of R&D) rather than purely transactional relationships.
• Demonstrating Commitment: High-priority targets often see a "busload" of the partner's executive committee visiting for final negotiations as a signal of serious commitment.
• Autonomy Expectations: Startups must decide if they desire full integration or semi-autonomous operation (e.g., Roche/Spark model allowing autonomy), as this impacts valuation and culture.

Evolution of Commercialization Models

• Standalone Ambition: Boards increasingly prefer structures that allow startups to remain standalone, such as retaining US commercial rights while out-licensing ex-US rights (e.g., LuxTerna/Novartis deal).
• Niche Manufacturing Control: For specialized modalities like gene therapy/AAVs, partners may allow the acquired entity to retain control of manufacturing and distribution due to unique functional know-how requirements.
• Traditional vs. Modern: The traditional model of full handoff to big pharma for development and distribution is shifting toward co-development or split-rights models to maximize long-term value for the innovator.